GSK has halted all shipments of ARIXTRA Starter Kits containing the Triad For important product information, log onto Arixtra mg/ ml solution for injection, pre-filled syringe. 2. .. Detailed information on this medicinal product is available on the website of the European . Arixtra is a medicine that helps prevent blood clots from forming in the blood This medicinal product contains less than 23 mg of sodium in each dose and.
Clin Appl Thromb Hemost. Patients should be sitting prescribint supine during administration. Initiate concurrent warfarin as soon as possible, 1 usually within 72 hours of fondaparinux injection; 1 20 ACCP recommends initiating warfarin simultaneously on the first day of fondaparinux treatment.
J Am Coll Cardiol. Anemia, fever, nausea, edema, constipation, rash, vomiting, insomnia, increased wound drainage, hypokalemia, urinary tract infection, dizziness, purpura, hypotension, confusion, bullous eruption, urinary retention, hematoma, major bleeding, diarrhea, dyspepsia, postoperative hemorrhage, headache. Prevention of VTE in nonorthopedic surgical patients: A synthetic pentasaccharide for the prevention of deep- vein thrombosis.
In healthy adults, distributes mainly in blood and only to a minor extent in extravascular fluid. If pharmacologic prophylaxis is indicated in patients undergoing general surgery, ACCP states that an LMWH or low-dose heparin is preferred; fondaparinux may be considered when both an LMWH and heparin are contraindicated or not available.
Platelet function or global clotting function tests e. Consider potential benefits versus risks of spinal or epidural anesthesia or spinal puncture in patients receiving or being considered for thromboprophylaxis with anticoagulants. Administer by sub-Q injection into fatty tissue, alternating injection sites daily e. The activity of fondaparinux sodium is measured based on plasma drug concentrations quantified by anti-factor Xa activity using fondaparinux as the calibrator.
Amended economic impact analysis of final rule requiring use of labeling on natural rubber containing devices.
Discontinue platelet-aggregation inhibitors prior to initiation of fondaparinux 1 In general, pharmacologic thromboprophylaxis is recommended only in such patients considered to be at high risk of venous thromboembolism. Prevention of postoperative DVT and PE in patients undergoing hip-fracture, hip-replacement, or knee-replacement surgery.
If fondaparinux therapy is to be continued after hospital discharge, importance of instructing patient on proper administration of the drug, including injection technique. Antithrombotic therapy for VTE disease: Optimal timing between administration of fondaparinux and neuraxial procedures not known. Discontinue platelet-aggregation inhibitors prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 A randomized double-blind trial.
If coadministration is essential, monitor patients closely Risk increased by use of indwelling epidural catheters or by concomitant use of drugs affecting hemostasis e. Treatment and prevention of heparin-induced thrombocytopenia: Discontinue NSAIAs prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely Importance of patients informing clinicians including dentists that they are receiving fondaparinux therapy before scheduling any invasive procedures.
VTE, thrombophilia, antithrombotic therapy, and pregnancy: Has been administered at an initial dose of 2. Periodic routine blood counts, including platelet counts, and tests for occult blood in stool recommended.
The pharmacokinetics of fondaparinux sodium in healthy volunteers. Distributed into milk in rats; not known whether distributed into human milk. Am J Health-Syst Pharm.
Discontinue oral anticoagulants prior to initiation of fondaparinux 1 40 If coadministration is essential, monitor patients closely 1 Importance of informing patients that concomitant use of aspirin or other NSAIAs can increase risk of bleeding, and to discontinue use of these drugs whenever possible.
Arixxtra with extreme caution in patients with an increased risk of hemorrhage e.
If PCI informayion performed while a patient is receiving fondaparinux, administer an additional anticoagulant with anti-factor IIa antithrombin activity because of the risk of catheter thrombosis. Bridgewater, NJ; Jul. Research Triangle Park, NC: Fondaparinux or enoxaparin for the initial treatment of symptomatic deep venous thrombosis: